After the U.S. Preventive Services Task Force released a draft recommendation statement on screening for cervical cancer, Leerink noted that the newly released draft USPSTF recommendations maintain co-testing as a Grade A recommended test, which the firm argues lifts a “minor overhang” on Hologic (HOLX) and the company’s “market-leading” AptimaHPV/ThinPrep cervical cancer screening test. Given co-testing maintained its USPSTF recommendation, the firm believes physicians will continue to utilize this procedure, so it sees today’s news as “an incremental positive” for Hologic, on which the firm has an Outperform rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- USPSTF draft guidance on cervical cancer positive for Hologic, says BTIG
- Hologic Expands Board with Martin Madaus Appointment
- Hologic initiated with a Hold at Jefferies
- Hologic research showis Genius AI Detection performs across diverse populations
- Hologic Updates Executive Compensation Agreements for 2025